Login
$BDSX
$9.00 +$0.00 (0.0%) After hours

$BDSX 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation

On November 2, 2026, it was agreed that the employment of Kieran O’Kane, Chief Commercial Officer of Biodesix, Inc. (the “Company”) would end effective November 2, 2026 (the “Separation Date”). Mr. O’Kane will be eligible for separation ...

05 Nov 2026 8-K: Results of Operations and Financial Condition

Delivered total revenue of $24.0 million, an increase of 10% year over year

05 Aug 2026 8-K: Results of Operations and Financial Condition

Delivered $26.9 million in revenue, representing 34% growth in Q2 2026;

20 May 2026 8-K: Submission of Matters to a Vote of Security Holders

Biodesix, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”) on May 19, 2026. At the Annual Meeting, the Company’s stockholders voted on: (i) the election of two Class III director nominees to serve ...

04 May 2026 8-K: Results of Operations and Financial Condition

Delivered $25.6 million in revenue representing 42% growth in Q1 2026;

26 Feb 2026 8-K: Results of Operations and Financial Condition

Delivered 41% revenue growth and 83% gross margin in Q4 2025;

03 Nov 2025 8-K: Results of Operations and Financial Condition

Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024;

01 Oct 2025 8-K: Other Events

On September 26, 2025, Biodesix, Inc., a Delaware corporation (the “Company”) received a letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compli...

15 Sep 2025 8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year

Biodesix, Inc., a Delaware corporation (the “Corporation”), does hereby certify as follows:

11 Sep 2025 8-K: Other Events

Louisville, CO September 11, 2025 — Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix” or the “Company”), a leader in personalized diagnostics, today announced a one-for-twenty reverse stock split (the “Reverse Stock Split”) of the Company’s comm...

07 Aug 2025 8-K: Results of Operations and Financial Condition

Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024;

21 May 2025 8-K: Submission of Matters to a Vote of Security Holders

Biodesix, Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”) on May 20, 2025. At the Annual Meeting, the Company’s stockholders voted on: (i) the election of two Class II director nominees to serve u...

13 May 2025 8-K: Results of Operations and Financial Condition

Total Q1 2025 Revenue of $18.0 million, an increase of 21% over Q1 2024;

17 Apr 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

28 Mar 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On March 24, 2025, Biodesix, Inc. (the “Company”) received written notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days...

03 Mar 2025 8-K: Results of Operations and Financial Condition

Total Revenue of $71.3 million for FY2024, growing 45% over FY2023;

10 Jan 2025 8-K: Results of Operations and Financial Condition

Grew full-year revenue to an estimated $71.3 million, an increase of 45%

01 Nov 2024 8-K: Results of Operations and Financial Condition

Biodesix Announces Third Quarter 2024 Results and Highlights

15 Aug 2024 8-K: Regulation FD Disclosure

Exhibit 99.1 Corporate Presentation Biodesix is a blood-based lung diagnostic company addressing a large unmet need with limited competition © 2024 Biodesix, Inc. All rights reserved. 1 3Q24

07 Aug 2024 8-K: Results of Operations and Financial Condition

Biodesix Announces Second Quarter 2024 Results and Highlights

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support